Vericel: Strong MACI-Driven Performance, Robust Balance Sheet, and Multi-Pronged Growth Catalysts Support Buy Rating and $60 Target

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Vericel, with a price target of $60.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors tied to Vericel’s strong recent performance and financial profile. The company closed FY2025 at the top end of its revenue guidance with $276M in sales, driven primarily by robust growth in MACI, and delivered its second straight year of GAAP profitability supported by high gross and EBITDA margins. Vericel also maintains a solid balance sheet with about $200M in cash and no debt, while operational metrics such as record MACI implants, biopsies, and an expanded base of trained surgeons underscore the strength and scalability of the current business.

Swayampakula Ramakanth’s rating is based on expectations that multiple growth initiatives can further enhance revenue and profitability over the medium term. These include the ramp-up of commercial manufacturing at a new facility, the planned international expansion of MACI starting in 2027, and the Phase 3 MASCOT trial for MACI Ankle, which could significantly enlarge MACI’s addressable market by 2030. In addition, management’s strategy to use a portfolio-based, cross-selling approach for its burn care products should deepen penetration of a substantial U.S. market. The company’s mid-term 2029 targets of $500M in revenue, higher operating cash flow, and increased margins provide further support for the $60 price target and underpin the favorable risk-reward profile implied in the Buy recommendation.

According to TipRanks, Ramakanth is a 5-star analyst with an average return of 18.4% and a 42.40% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Delcath Systems, and Janux Therapeutics Inc.

In another report released on January 16, TipRanks – Google also reiterated a Buy rating on the stock with a $41.00 price target.